Condition: Neuroendocrine Tumor Grade 2 · Neuroendocrine Tumors · Sponsor: Abramson Cancer Center at Penn Medicine
This is a Phase 2 evaluation of hepatic-progression free survival among patients with Grade 2 liver-dominant NET metastases undergoing combination therapy with CapTem and Y90 radioembolization.The hypothesis is to confirm safety and to assess if disease control is improved relative to expectation from either therapy alone. A Grade 3 arm was added in 2025.
This description comes directly from the study's public registry record.
Michael Soulen, MD · 855-216-0098 · michael.soulen@pennmedicine.upenn.edu
Veronica Faris · Veronica.Faris@pennmedicine.upenn.edu
Always discuss trial participation with your own doctor first.
| UC San Diego | La Jolla, California, United States | Recruiting |
| University of Miami Miller School of Medicine-Sylvester Cancer Center | Miami, Florida, United States | Recruiting |
| Roswell Park Comprehensive Cancer Center | Buffalo, New York, United States | Recruiting |
| University of Pennsylvania | Philadelphia, Pennsylvania, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04339036